Co-Diagnostics selects Maxim Group as financial advisor for CoSara Diagnostics

Co-Diagnostics (CODX) announced that it has engaged Maxim Group as its exclusive financial advisor to assist the Company in identifying potential strategic alternatives for the Company’s Indian joint venture, CoSara Diagnostics, including a merger with a Special Purpose Acquisition Company or similar entity listed on a U.S. national securities exchange. Established in 2017, CoSara is a joint venture between Co-Diagnostics and Synbiotics, a group company of Asence, a U.S. company that specializes in supplying pharmaceutical products to international markets. Asence and Synbiotics are both subsidiaries of Ambalal Sarabhai Enterprises, a publicly-listed company on the Bombay Stock Exchange. Using the core competencies of its partner companies, CoSara intends to manufacture and sell molecular diagnostics products to patients and healthcare providers in certain international markets with an initial focus on India.